Cancer Research UK-funded scientists have found evidence to suggest that low doses of Merck KGaA's cilengitide in laboratory studies can have the opposite effect to that expected and promote cancer growth, according to research published in Nature Medicine. The German drugmaker's investigational integrin inhibitor recently entered mid-stage testing (Marketletter March 23).
Lead study author, Andy Reynolds, said: "our study revealed a previously unknown mechanism through which drugs such as cilengitide behave. It showed that, while higher concentrations of cilengitide can block angiogenesis, lower concentrations can actually stimulate the supply of blood to the tumor and can promote its growth. These results may explain why initial results from early-stage clinical trials have not been as promising as hoped."
Commenting on the findings, Merck KGaA spokesperson Phyllis Carter said: "the data presented in this paper are of interest to the overall debate as to the mode of action of integrin inhibitors. However, it does not reflect previous findings in other preclinical models in vivo or in vitro, either as single agent or in combination. Even more important the observations of Reynolds et al in preclinical models have not been reflected in clinical settings."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze